Sugi Predict

Sugi Predict / Compounds / SCHEMBL56760

SCHEMBL56760

SCHEMBL56760

O=C(Cc1cccc(O)c1)OCc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.73
▸ MAPK1 P28482 1/20 0.73
▸ L3MBTL1 Q9Y468 1/20 0.73
▸ CTBP2 P56545 1/20 0.53
▸ PAM P19021 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ ENPP2 Q13822 2/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ SLC6A2 P23975 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49
▸ KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27499661 0.85 ALDH1A1 (0.92) ALDH1A1MAPK1L3MBTL1PAMENPP2
SCHEMBL361779 0.85 ALDH1A1 (1.00) ALDH1A1MAPK1L3MBTL1PAMENPP2
SCHEMBL6784181 0.83 ALDH1A1 (0.96) ALDH1A1MAPK1L3MBTL1PAMENPP2
SCHEMBL56986 0.83 TDP1 (0.59) ALDH1A1MAPK1L3MBTL1NPC1RAB9A
SCHEMBL5441092 0.83 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1PAMENPP2
SCHEMBL11686224 0.83 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1CTBP2PAM
SCHEMBL21012091 0.83 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1CTBP2PAM
SCHEMBL31310151 0.83 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1NPC1RAB9A
SCHEMBL4673587 0.83 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1PAMENPP2
SCHEMBL1724245 0.83 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1PAMENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20250235547-A1 ANTIBODY-DRUG CONJUGATE UBE CORPORATION (JP) 2025-07-24 — — US disclosed
US-20250170267-A1 ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF UBE CORPORATION (JP) 2025-05-29 — — US disclosed
EP-4487873-A1 ANTIBODY-DRUG CONJUGATE UBE Corporation (JP) 2025-01-08 — — EP disclosed
EP-4487874-A1 ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF UBE Corporation (JP) 2025-01-08 — — EP disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023163227-A1 ANTIBODY-DRUG CONJUGATE ＵＢＥ株式会社 2023-08-31 — — WO disclosed
WO-2023163234-A1 ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF ＵＢＥ株式会社 2023-08-31 — — WO disclosed
EP-3514160-B1 NAHLSGEN OPTICAL RESOLUTION METHOD UNIV KYOTO (JP) 2021-08-11 — — EP disclosed
US-10774098-B2 Nahlsgen optical resolution method KYOTO UNIVERSITY (JP) 2020-09-15 — — US disclosed
US-20090163725-A1 PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF HIRATAKE, GOU (JP) 2009-06-25 — — US disclosed
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. 2009-04-09 — — US disclosed
WO-2009036016-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2009-03-19 — — WO disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 — — US disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 — — US disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 — — US disclosed
EP-1940767-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2008-07-09 — — EP disclosed
WO-2007030567-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2007-03-15 — — WO disclosed
WO-2007030567-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2007-03-15 — — WO disclosed
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses GENFIT (FR) 2006-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249137-A1 PPAR active compounds PPARG, PPARA, PPARD ALDH1A1 789/4885MAPK1 2193/4885L3MBTL1 3414/4885
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses AADAC, NAT1, PARN ALDH1A1 845/4885MAPK1 3624/4885L3MBTL1 2320/4885
US-20090093507-A1 CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY CDK3, CDKL1, CDKL3 ALDH1A1 2650/4885MAPK1 975/4885L3MBTL1 1672/4885
US-10774098-B2 Nahlsgen optical resolution method HACL2, HAO2, HPD ALDH1A1 150/4885MAPK1 486/4885L3MBTL1 1313/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B ALDH1A1 2349/4885MAPK1 3767/4885L3MBTL1 1884/4885
US-20090163725-A1 PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF PPA1, G6PD, PHOSPHO1 ALDH1A1 1716/4885MAPK1 1065/4885L3MBTL1 3435/4885
US-20250235547-A1 ANTIBODY-DRUG CONJUGATE LDHB, LDHA, DLST ALDH1A1 206/4885MAPK1 2411/4885L3MBTL1 61/4885
US-20250170267-A1 ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF DLST, LANCL1, DDOST ALDH1A1 216/4885MAPK1 1374/4885L3MBTL1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.